Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2019 May 26

PMID 31127527

Citations 3

Authors

Carl G Gottschalk

Avik Roy

Malabendu Jana

Madhuchhanda Kundu

Kalipada Pahan

Affiliations

Soon will be listed here.

Abstract

Nuclear receptor related 1 protein (Nurr1) is an important transcription factor required for differentiation and maintenance of midbrain dopaminergic (DA) neurons. Since decrease in Nurr1 function either due to diminished expression or rare mutation is associated with Parkinson's disease (PD), upregulation of Nurr1 may be beneficial for PD. However, such mechanisms are poorly understood. This study underlines the importance of peroxisome proliferator-activated receptor (PPAR)α in controlling the transcription of Nurr1. Our mRNA analyses followed by different immunoassays clearly indicated that PPARα agonist gemfibrozil strongly upregulated the expression of Nurr1 in wild-type, but not PPARα, DA neurons. Moreover, identification of conserved PPRE in the promoter of Nurr1 gene followed by chromatin immunoprecipitation analysis, PPRE luciferase assay, and manipulation of Nurr1 gene by viral transduction of different PPARα plasmids confirmed that PPARα was indeed involved in the expression of Nurr1. Finally, oral administration of gemfibrozil increased Nurr1 expression in vivo in nigra of wild-type, but not PPARα, mice identifying PPARα as a novel regulator of Nurr1 expression and associated protection of DA neurons.

Citing Articles

Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.

Paidi R, Jana M, Mishra R, Dutta D, Pahan K J Immunol. 2021; 207(10):2521-2533.

PMID: 34645689 PMC: 8664124. DOI: 10.4049/jimmunol.2100144.

Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo.

Dutta D, Jana M, Majumder M, Mondal S, Roy A, Pahan K Nat Commun. 2021; 12(1):5382.

PMID: 34508096 PMC: 8433339. DOI: 10.1038/s41467-021-25767-1.

Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.

Gottschalk C, Jana M, Roy A, Patel D, Pahan K J Neurosci. 2021; 41(10):2287-2300.

PMID: 33514677 PMC: 8018777. DOI: 10.1523/JNEUROSCI.3018-19.2021.

References

Vazquez M, Merlos M, Adzet T, Laguna J . Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. Br J Pharmacol. 1996; 117(6):1155-62. PMC: 1909812. DOI: 10.1111/j.1476-5381.1996.tb16710.x. View

Arenas E . Engineering a dopaminergic phenotype in stem/precursor cells: role of Nurr1, glia-derived signals, and Wnts. Ann N Y Acad Sci. 2005; 1049:51-66. DOI: 10.1196/annals.1334.007. View

Roy A, Pahan K . Prospects of statins in Parkinson disease. Neuroscientist. 2011; 17(3):244-55. PMC: 3132406. DOI: 10.1177/1073858410385006. View

Jacobsen K, MacDonald H, Lemonde S, Daigle M, Grimes D, Bulman D . A Nurr1 point mutant, implicated in Parkinson's disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription. Neurobiol Dis. 2007; 29(1):117-22. DOI: 10.1016/j.nbd.2007.08.003. View

Saijo K, Winner B, Carson C, Collier J, Boyer L, Rosenfeld M . A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009; 137(1):47-59. PMC: 2754279. DOI: 10.1016/j.cell.2009.01.038. View

Corbett G, Gonzalez F, Pahan K . Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A. 2015; 112(27):8445-50. PMC: 4500265. DOI: 10.1073/pnas.1504890112. View

Roy A, Kundu M, Jana M, Mishra R, Yung Y, Luan C . Identification and characterization of PPARα ligands in the hippocampus. Nat Chem Biol. 2016; 12(12):1075-1083. PMC: 5110367. DOI: 10.1038/nchembio.2204. View

Hammond S, Safe S, Tjalkens R . A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro. Neurosci Lett. 2015; 607:83-89. PMC: 4631643. DOI: 10.1016/j.neulet.2015.09.015. View

Oh S, Chang M, Song J, Rhee Y, Joe E, Lee H . Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease. EMBO Mol Med. 2016; 8(2):171. PMC: 4734846. DOI: 10.15252/emmm.201506162. View

10.

Roy A, Jana M, Corbett G, Ramaswamy S, Kordower J, Gonzalez F . Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor α. Cell Rep. 2013; 4(4):724-37. PMC: 3804033. DOI: 10.1016/j.celrep.2013.07.028. View

11.

Pinto F, Mazza S . Psychic symptoms in levodopa treatment of Parkinsons' disease. II. Riv Neurobiol. 1971; 17(2):155-9. View

12.

Le W, Pan T, Huang M, Xu P, Xie W, Zhu W . Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008; 273(1-2):29-33. PMC: 2572302. DOI: 10.1016/j.jns.2008.06.007. View

13.

Lallier S, Graf A, Waidyarante G, Rogers L . Nurr1 expression is modified by inflammation in microglia. Neuroreport. 2016; 27(15):1120-7. PMC: 5016245. DOI: 10.1097/WNR.0000000000000665. View

14.

Rodriguez-Traver E, Solis O, Diaz-Guerra E, Ortiz O, Vergano-Vera E, Mendez-Gomez H . Role of Nurr1 in the Generation and Differentiation of Dopaminergic Neurons from Stem Cells. Neurotox Res. 2015; 30(1):14-31. DOI: 10.1007/s12640-015-9586-0. View

15.

Carmine A, Buervenich S, Galter D, Jonsson E, Sedvall G, Farde L . NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits. Am J Med Genet B Neuropsychiatr Genet. 2003; 120B(1):51-7. DOI: 10.1002/ajmg.b.20033. View

16.

Wang T, Hay J . Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease. Front Neurosci. 2015; 9:433. PMC: 4641903. DOI: 10.3389/fnins.2015.00433. View

17.

Chandra G, Kundu M, Rangasamy S, Dasarathy S, Ghosh S, Watson R . Increase in Mitochondrial Biogenesis in Neuronal Cells by RNS60, a Physically-Modified Saline, via Phosphatidylinositol 3-Kinase-Mediated Upregulation of PGC1α. J Neuroimmune Pharmacol. 2017; 13(2):143-162. PMC: 5928179. DOI: 10.1007/s11481-017-9771-4. View

18.

Roy A, Pahan K . Ankyrin repeat and BTB/POZ domain containing protein-2 inhibits the aggregation of alpha-synuclein: implications for Parkinson's disease. FEBS Lett. 2013; 587(21):3567-74. PMC: 3929398. DOI: 10.1016/j.febslet.2013.09.020. View

19.

Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A . α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012; 4(163):163ra156. DOI: 10.1126/scitranslmed.3004676. View

20.

Tan E, Chung H, Chandran V, Tan C, Shen H, Yew K . Nurr1 mutational screen in Parkinson's disease. Mov Disord. 2004; 19(12):1503-5. DOI: 10.1002/mds.20246. View